Terumo Corporation has announced the successful completion of its acquisition of a drug product plant and associated quality control laboratory operations from WuXi Biologics in Leverkusen, Germany.
The plant covers an area of 13,000㎡. It has around 150 employees.
This strategic acquisition reinforces Terumo’s position in the contract development and manufacturing organization (CDMO) sector, expands its integrated service offerings, and enhances its ability to support biopharmaceutical companies in launching effective injectable treatment options.
By integrating Terumo’s expertise, advanced technologies, and skilled team, the company aims to accelerate innovation and deliver greater value to pharmaceutical customers and their patients.
The newly acquired Leverkusen Drug Product Plant features state-of-the-art facilities compliant with current Good Manufacturing Practice (cGMP) standards and is staffed by highly skilled professionals with deep production know-how.
Leveraging these assets, Terumo will offer fill & finish services for vials and polymer prefillable syringes, including device assembly.
This move will enable the company to meet the growing demand for CDMO services, particularly in Europe and the United States, driven by the rapid expansion of the biopharmaceutical market.
Currently, Terumo operates three CDMO production facilities at the Kofu, Fujinomiya, and Yamaguchi plants in Japan. The company has consistently enhanced its production capacity in line with the expansion of the CDMO business.
In fact, Terumo has strengthened its capabilities by expanding production lines at the Yamaguchi factory. Additionally, new production lines are being installed in a newly constructed building at the Kofu factory, scheduled for completion by the end of 2025.
With the establishment of this new CDMO base in Europe, Terumo is strengthening its global operations to better serve pharmaceutical companies both domestically and internationally.
